A
24.11
-0.69 (-2.78%)
| Previous Close | 24.80 |
| Open | 23.89 |
| Volume | 1,741,918 |
| Avg. Volume (3M) | 1,508,354 |
| Market Cap | 2,898,311,424 |
| Price / Sales | 253.94 |
| Price / Book | 2.09 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2025 - 12 May 2025 |
| Operating Margin (TTM) | -4,069.63% |
| Diluted EPS (TTM) | -2.89 |
| Quarterly Revenue Growth (YOY) | 35.60% |
| Total Debt/Equity (MRQ) | 0.48% |
| Current Ratio (MRQ) | 15.73 |
| Operating Cash Flow (TTM) | -300.87 M |
| Levered Free Cash Flow (TTM) | -197.47 M |
| Return on Assets (TTM) | -21.60% |
| Return on Equity (TTM) | -33.47% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Avidity Biosciences, Inc. | Bearish | Bullish |
AIStockmoo Score
0.1
| Analyst Consensus | 3.0 |
| Insider Activity | -1.5 |
| Price Volatility | 1.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | 0.10 |
|
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 5.03% |
| % Held by Institutions | 107.34% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 72.00 (BMO Capital, 198.63%) | Buy |
| 72.00 (HC Wainwright & Co., 198.63%) | Buy | |
| Median | 67.00 (177.89%) | |
| Low | 48.00 (B of A Securities, 99.09%) | Buy |
| Average | 64.56 (167.77%) | |
| Total | 9 Buy | |
| Avg. Price @ Call | 30.63 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 09 Apr 2025 | 60.00 (148.86%) | Buy | 24.80 |
| 17 Mar 2025 | 60.00 (148.86%) | Buy | 33.83 | |
| HC Wainwright & Co. | 18 Mar 2025 | 72.00 (198.63%) | Buy | 30.48 |
| 17 Mar 2025 | 72.00 (198.63%) | Buy | 33.83 | |
| Chardan Capital | 17 Mar 2025 | 65.00 (169.60%) | Buy | 33.83 |
| 28 Feb 2025 | 65.00 (169.60%) | Buy | 30.64 | |
| Citigroup | 13 Mar 2025 | 70.00 (190.34%) | Buy | 32.13 |
| BMO Capital | 12 Mar 2025 | 72.00 (198.63%) | Buy | 32.61 |
| B of A Securities | 10 Mar 2025 | 48.00 (99.09%) | Buy | 30.04 |
| Scotiabank | 07 Mar 2025 | 70.00 (190.34%) | Buy | 30.29 |
| Barclays | 28 Feb 2025 | 57.00 (136.42%) | Buy | 30.64 |
| RBC Capital | 21 Jan 2025 | 67.00 (177.89%) | Buy | 30.84 |
| Show more | ||||
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |